UBS Maintains a 'Buy' on Walgreen (WAG); January Comps Will Represent First Month Without ESRX
Tweet
Share
E-mailGet Alerts WAG Hot Sheet
Price: $76.05 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Buy' on Walgreen (NYSE: WAG) price target lowered from $40 to $38.
UBS analyst says, "For January, we are projecting WAG monthly same-store sales of -6.7%, which includes a -10% pharmacy comp, and a +0.7% front-end comp (Table 2). The Rx comp assumes a low-teens recapture rate of ESRX scripts in Jan/Feb, with a trend toward 25% recapture by year-end. We expect WAG January total company sales of $5,654 mil (-4.7% y-o-y). With minimal initial cost-cutting (as per WAG mgmt), this translates to $0.72 EPS for upcoming F2Q12, well below $0.79 Street."
"...Further, we assume WAG’s raw SG&A dollar spend increases annually by +1-3% (down materially from historical trend), and also assume modest gross margin expansion with culling of low-margin ESRX payor. The overall changes lead to FY12 EPS cut from $2.73 to $2.48, FY13 from $2.95 to $2.68, and FY14 from $3.34 to $3.04."
Other stocks of note: Express Scripts (Nasdaq: ESRX), CVS Caremark (NYSE: CVS)
For an analyst ratings summary and ratings history on Walgreen click here. For more ratings news on Walgreen click here.
Shares of Walgreen closed at $33.36 yesterday.
UBS analyst says, "For January, we are projecting WAG monthly same-store sales of -6.7%, which includes a -10% pharmacy comp, and a +0.7% front-end comp (Table 2). The Rx comp assumes a low-teens recapture rate of ESRX scripts in Jan/Feb, with a trend toward 25% recapture by year-end. We expect WAG January total company sales of $5,654 mil (-4.7% y-o-y). With minimal initial cost-cutting (as per WAG mgmt), this translates to $0.72 EPS for upcoming F2Q12, well below $0.79 Street."
"...Further, we assume WAG’s raw SG&A dollar spend increases annually by +1-3% (down materially from historical trend), and also assume modest gross margin expansion with culling of low-margin ESRX payor. The overall changes lead to FY12 EPS cut from $2.73 to $2.48, FY13 from $2.95 to $2.68, and FY14 from $3.34 to $3.04."
Other stocks of note: Express Scripts (Nasdaq: ESRX), CVS Caremark (NYSE: CVS)
For an analyst ratings summary and ratings history on Walgreen click here. For more ratings news on Walgreen click here.
Shares of Walgreen closed at $33.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
